Date: 23 Oct 2012
Influence of Piperine on the Pharmacokinetics of Nevirapine under Fasting Conditions
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Nevirapine is a potent non-nucleoside inhibitor of HIV-1 reverse transcriptase and is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. Piperine (1-piperoylpiperidine) is an alkaloid and the main pungency principle in both black and long pepper. There are indications that piperine inhibits, rather than stimulates, drug metabolism in most cases, thus increasing the bioavailability and effect of some drugs.
Methods: This was a crossover, placebo-controlled pilot study conducted in a total of eight healthy adult males aged 20–40 years. Subjects were randomly assigned to receive piperine 20mg or placebo each morning for 6 days, and on day 7, nevirapine 200mg plus piperine 20mg or nevirapine plus placebo in a crossover fashion. Blood samples were collected from 1 to 144 hours post-dose for pharmacokinetic analysis.
Results: Mean maximum plasma concentration (Cmax), area under the plasma concentration-time curve from 0 hours to the last measurable concentration (Clast) [AUCt], AUC extrapolated to infinity (AUC∞) and Clast values of nevirapine were increased by approximately 120%, 167%, 170% and 146%, respectively, when co-administered with piperine. The treatments were well tolerated, indicating few or no clinical adverse effects.
Conclusion: This pilot study provided evidence for enhanced bioavailability of nevirapine when administered with piperine. Further in-depth studies in a large number of patients receiving different dosage regimens are required to confirm these results and further our understanding of a possible clinical advantage arising from the bioenhancement capabilities of piperine in the treatment of HIV infection.
UNAIDS: the Joint United Nations Programme on HIV/AIDS Web site [online]. Available at URL: http://www.unaids.org/ Unaids/EN/Resources/Epidemiology/epidemicupdateslides.asp / Unaids/EN/Resources/Epidemiology/epidemicupdateslides.asp [Accessed 2004 Aug 17]
US Department of Health and Human Services (DHHS). HIV/AIDS medical practice guidelines [online]. Available at URL: http://www.aidsinfo.nih.gov/guidelines/ [Accessed 2004 Aug
Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20: 11–9PubMedCrossRef
Lamson MJ, Cort S, Sabo JP, et al. Assessment of nevirapine oral bioavailability in healthy volunteers following oral and intravenous administration. Pharm Res 1995; 12: S–415
Viramune (nevirapine) [online]. Available from URL: http://www.rxlist.com/cgi/generic/nevira_cp.htm [Accessed 2007 Oct 19]
Riska P, Lamson M, MacGregor T, et al. Disposition and biotransformation of the antiretroviral drug nevirapine in humans. Drug Metab Dispos 1999 Aug; 27 (8): 895–901PubMed
Baily DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46: 101–10CrossRef
Zutshi RK, Singh R, Zutshi U, et al. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985; 33: 223–4PubMed
Singh J, Dubey RK, Atal CK. Piperine-mediated inhibition of glucuronidation activity in isolated epithelial cells of the guinea-pig small intestine: evidence that piperine lowers the endogenous UDP-glucuronic acid content. J Pharmacol Exp Ther 1986; 236: 488–93PubMed
Viramune (nevirapine) [product information]. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals, 1999
Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Experiment Therapeut 2002; 302: 645–50CrossRef
- Influence of Piperine on the Pharmacokinetics of Nevirapine under Fasting Conditions
Drugs in R & D
Volume 8, Issue 6 , pp 383-391
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors